CD8A and neoplasm: For example, in a preclinical study, tumor-specific CD4 and CD8 T cells were found to metabolically reprogram phosphoenolpyruvate carboxylation kinase 1 (PCK1) by increasing the glycolytic metabolite phosphoenolpyruvate (PEP) to enhance the antitumor response (Ho et al., 2015).